Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
75.78
Aug 06 • 3:59 PM ET Dollar change-2.36 Percentage change(-3.03%)
Aftermarket Close
76.00
Aftermarket • 5:00 PM ET Dollar change+0.22 Percentage change(0.29%)
Aug 05, 6:25 PMLivaNova posts record Q2 with adjusted EPS $1.26, raises 2026 revenue and EPS outlook, cuts 2026 adjusted free cash flow guidance to $140–$160M
Index
RUT
Market Cap
4.16B
Enterprise Value
4.00B
Income
188.57M
Sales
1.47B
Book/sh
24.07
Cash/sh
9.40
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
3300
IPO
Feb 11, 1993
P/E
22.48
Forward P/E
16.18
PEG
1.58
P/S
2.83
P/B
3.15
P/C
8.06
P/FCF
28.07
EV/EBITDA
15.44
EV/Sales
2.72
Quick Ratio
1.21
Current Ratio
1.45
Debt/Eq
0.27
LT Debt/Eq
0.26
Option/Short
Yes / Yes
EPS (ttm)
3.37
EPS next Y
4.68
EPS next Q
1.05
EPS this Y
11.34%
EPS next Y
7.83%
EPS next 5Y
10.25%
EPS past 3/5Y
-40.20% 9.06%
Sales past 3/5Y
10.75% 8.24%
EPS Y/Y TTM
148.08%
Sales Y/Y TTM
12.39%
EPS Q/Q
288.72%
Sales Q/Q
10.80%
Insider Own
0.42%
Insider Trans
-1.28%
Inst Own
110.69%
Inst Trans
4.39%
ROA
7.33%
ROE
15.41%
ROIC
11.33%
Gross Margin
66.94%
Oper. Margin
14.51%
Profit Margin
12.81%
SMA20
-5.73%
SMA50
-4.43%
SMA200
13.11%
Trades
Shs Outstand
55.05M
Shs Float
54.70M
52W High
85.76 -11.64%
52W Low
45.64 66.04%
Volatility
4.37% 3.21%
ATR (14)
2.97
RSI (14)
40.40
Beta
0.86
Rel Volume
1.22
Avg Volume
765.78K
Volume
932,460
Perf Week
-6.50%
Perf Month
-8.16%
Perf Quarter
14.37%
Perf Half Y
15.82%
Perf YTD
23.16%
Perf Year
60.01%
Perf 3Y
32.74%
Perf 5Y
-10.13%
Perf 10Y
24.23%
Prev Close
78.14
Price
75.78
Change
-3.03%
Date Action Analyst Rating Change Price Target Change
Dec-19-25Initiated KeyBanc Capital Markets Overweight $81
Oct-01-25Downgrade Goldman Buy → Neutral $55
May-20-25Upgrade Wolfe Research Peer Perform → Outperform $60
Feb-26-25Downgrade Wolfe Research Outperform → Peer Perform
Oct-04-24Initiated Goldman Buy $65
Sep-17-24Upgrade Robert W. Baird Neutral → Outperform $55 → $66
Mar-20-24Reiterated Needham Buy
Feb-20-24Upgrade Mizuho Neutral → Buy $60 → $70
Sep-06-23Initiated HSBC Securities Hold $52
Jul-19-23Initiated Robert W. Baird Neutral $56
Aug-05-26 06:03PM
03:02PM
08:24AM
06:08AM
06:00AM
09:00AM Loading…
Jun-24-26 09:00AM
Jun-16-26 10:57AM
Jun-11-26 01:44PM
Jun-05-26 09:00AM
May-21-26 09:15AM
May-19-26 08:00AM
May-06-26 04:52PM
08:32AM
06:11AM
06:00AM
05:05PM Loading…
Apr-20-26 05:05PM
Mar-27-26 10:15AM
Mar-25-26 09:00AM
Mar-19-26 08:30AM
Mar-10-26 11:40AM
11:39AM
11:21AM
Mar-05-26 12:00PM
Feb-25-26 03:29PM
02:28PM
02:01PM
12:36PM
12:30PM
12:15PM
06:07AM
06:00AM Loading…
06:00AM
Feb-24-26 07:30PM
Feb-02-26 02:51PM
Jan-30-26 02:31PM
Jan-29-26 09:03AM
08:21AM
08:03AM
Jan-28-26 05:10PM
01:46PM
Jan-20-26 09:00AM
Dec-23-25 09:00AM
Dec-03-25 09:00AM
Dec-02-25 09:00AM
Nov-25-25 09:00AM
Nov-24-25 07:21PM
09:00AM
Nov-13-25 07:40PM
Nov-12-25 03:26PM
Nov-06-25 10:00PM
Nov-05-25 07:10AM
06:13AM
06:00AM
Oct-31-25 09:40AM
Oct-23-25 09:00AM
Oct-08-25 09:00AM
Oct-07-25 09:00AM
Oct-02-25 09:10AM
Oct-01-25 09:44AM
Sep-30-25 09:40AM
Sep-08-25 04:34PM
Sep-04-25 09:00AM
Aug-22-25 09:00AM
Aug-18-25 09:00AM
Aug-15-25 10:10AM
Aug-06-25 07:35PM
07:10AM
06:11AM
06:00AM
Aug-05-25 07:45AM
Aug-04-25 10:02AM
Jul-30-25 11:49AM
Jul-29-25 04:38AM
Jul-16-25 09:39AM
Jul-11-25 08:12PM
Jul-09-25 09:00AM
Jun-25-25 11:37AM
Jun-10-25 08:33PM
Jun-06-25 09:58AM
Jun-05-25 08:15AM
08:00AM
Jun-04-25 08:00AM
May-15-25 08:00AM
May-08-25 03:10AM
May-07-25 11:31AM
07:15AM
06:14AM
06:00AM
05:45AM
May-06-25 06:05PM
May-01-25 05:15PM
Apr-25-25 04:30PM
Apr-14-25 09:51AM
Apr-10-25 04:32AM
Mar-26-25 08:00AM
Mar-04-25 11:56PM
10:12PM
Feb-26-25 02:04AM
Feb-25-25 08:32PM
07:10AM
06:10AM
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.
CEO & DirectorMr. Vladimir A. Makatsaria
Chief Financial OfficerMr. Alex Shvartsburg C.M.A.
Chief Human Resources OfficerMs. Natalia Sergeyevna Kozmina
Chief Innovation OfficerMr. Ahmet Tezel Ph.D.
VP & Chief Accounting OfficerMs. Lindsey Little
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WILVER PETER MDirectorJun 15 '26Option Exercise0.004,042010,780Jun 17 04:09 PM
SCHERMERHORN TODD CDirectorJun 15 '26Option Exercise0.004,042013,105Jun 17 04:09 PM
Bianchi FrancescoDirectorJun 15 '26Option Exercise0.004,042011,270Jun 17 04:09 PM
Bianchi FrancescoDirectorJun 15 '26Sale80.191,20096,2289,584Jun 17 04:09 PM
PODLOGAR SUSAN MDirectorJun 15 '26Option Exercise0.004,04206,128Jun 17 04:09 PM
Barry James ChristopherDirectorJun 15 '26Option Exercise0.004,04208,404Jun 17 04:09 PM
Tezel AhmetChief Innovation OfficerJun 15 '26Option Exercise0.002,96507,122Jun 17 04:09 PM
KOZY WILLIAM ADirectorJun 15 '26Option Exercise0.005,681038,248Jun 17 04:09 PM
Enxing Seng StacyDirectorJun 15 '26Option Exercise0.004,042015,793Jun 17 04:08 PM
Story BrookeDirectorJun 15 '26Option Exercise0.004,042010,274Jun 17 04:08 PM
Zurbay DonaldDirectorJun 15 '26Option Exercise0.002,56002,560Jun 17 04:08 PM
Bianchi FrancescoOfficerJun 15 '26Proposed Sale80.191,20096,228Jun 15 04:56 PM
Bianchi FrancescoDirectorMay 26 '26Sale75.751,800136,3507,228May 27 04:51 PM
Bianchi FrancescoOfficerMay 26 '26Proposed Sale75.751,800136,350May 26 04:37 PM
Tezel AhmetChief Innovation OfficerMar 30 '26Option Exercise0.003,40805,343Apr 01 05:20 PM
Poletti FrancoPresident, CardiopulmonaryMar 30 '26Option Exercise0.003,184012,125Apr 01 05:20 PM
Shvartsburg AlexChief Financial OfficerMar 30 '26Option Exercise0.0030,835057,515Apr 01 05:20 PM
Makatsaria VladimirChief Executive OfficerMar 30 '26Option Exercise0.0021,042025,326Apr 01 05:20 PM
Bolton StephaniePresident, Global EpilepsyMar 30 '26Option Exercise0.0017,815030,566Apr 01 05:20 PM
Kozmina NataliaChief Human Resources OfficerMar 30 '26Option Exercise0.006,38906,389Apr 01 05:20 PM
Poletti FrancoPresident, CardiopulmonaryMar 11 '26Option Exercise57.602,140123,26410,990Mar 13 05:25 PM
Poletti FrancoPresident, CardiopulmonaryDec 15 '25Option Exercise0.0096709,266Dec 17 04:06 PM
PODLOGAR SUSAN MDirectorDec 15 '25Option Exercise0.002,35502,355Dec 17 04:06 PM
Hutchinson Michael DamonSVP, CLO and Company SecretaryDec 15 '25Option Exercise0.002,25407,920Dec 17 04:06 PM
Story BrookeDirectorNov 18 '25Sale53.9425013,4856,232Nov 19 03:57 PM
Story BrookeDirectorNov 18 '25Proposed Sale53.9425013,485Nov 18 04:51 PM
Poletti FrancoPresident, CardiopulmonarySep 15 '25Option Exercise0.0064308,576Sep 17 04:05 PM
Bianchi FrancescoDirectorAug 25 '25Sale56.501,50084,7509,028Aug 27 04:17 PM
Bianchi FrancescoDirectorAug 25 '25Proposed Sale56.501,50084,750Aug 25 04:26 PM